Intec Pharma Ltd.

110 articles about Intec Pharma Ltd.

• Intec Announces $30 Million Private Placement Ahead of Decoy Merger

  7/26/2021

  Intec Pharma Ltd., announced that its wholly-owned subsidiary, Intec Parent, Inc., entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement.

• Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K

  3/17/2021

  Intec Pharma Ltd. announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission.

• Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma

  12/9/2020

  Intec Pharma Ltd. announces it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill platform for an undisclosed research program.

• Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/5/2020

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update.  "We maintain our focus on executing strategic partnerships and collaborations. As such, we were delighted in recent weeks to announce a new research collabor

• Intec Pharma Announces 1-for-20 Reverse Share Split

  10/29/2020

  - Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020 , and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq C

• Intec Pharma Announces New Research Collaboration Agreement with MSD

  10/8/2020

  Intec Pharma Ltd. announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA.

• Intec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/14/2020

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

• Intec Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  Intec Pharma Ltd. announces that the Company management will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference.

• Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering

  8/7/2020

  Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Aspire”) for the purchase and sale, in a registered direct offering, of 7,125,000 of the Company’s ordinary shares at a purchase price of $0.3511 per share, and pre-funded warrants to purchase 7,125,000 of the Company’s ordinary shares at a purchase price of $0.3411 per warrant, which represents the

• Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/5/2020

  Intec Pharma Ltd. announces financial results for the second quarter ended June 30, 2020 and provides a corporate update.

• Intec Pharma to Present at Jefferies Virtual Healthcare Conference

  5/28/2020

   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare Conference. Jefferies Virtual Healthcare Conference Date: June 2 – June 4, 2020 Company Presentation: Thursday, June 4, 2020 at 4:00 pm (ET) Presenter: Jeffrey A. Meckler ,

• Intec Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/11/2020

  Intec Pharma Ltd. announces financial results for the first quarter ended March 31, 2020 and provides a corporate update.

• Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update

  3/13/2020

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2019 and provides a corporate update. 

• Intec Pharma Announces Pricing of $6.5 Million Public Offering

  1/31/2020

  Intec Pharma Ltd. announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares and warrants to purchase up to 16,250,000 ordinary shares, at a public offering price of $0.40 per ordinary share.

• Intec Pharma Announces Proposed Public Offering - Jan. 30, 2020

  1/30/2020

  Intec Pharma Ltd. announced that it intends to offer and sell a combination of ordinary shares and warrants to purchase ordinary shares in an underwritten public offering.

• Intec Pharma Issues Letter to Shareholders

  1/9/2020

  Intec Pharma Ltd. provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill® platform, in a Letter to Shareholders.

• Intec Pharma Provides Update on Novartis Feasibility and Option Agreement

  12/11/2019

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill® (AP) for a proprietary Novartis compound, despite the AP having met the technical and pharmacokinetic (PK) clinical specifications set forth by Novartis

• Intec Pharma to Present at LD Micro's 12th Annual Main Event

  12/6/2019

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12th Annual LD Micro Main Event investor conference.

• Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital

  12/3/2019

  Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicago-based institutional investor.

• Intec Pharma to Participate in Jefferies London Healthcare Conference

  11/13/2019

  Intec Pharma Ltd. announces that Company management will participate in the Jefferies London Healthcare Conference..